Every Dubai clinic page selling breast augmentation reads roughly the same way. A complimentary consultation. A surgeon's credentials, and these are often genuinely checkable: board certification, a training hospital, a headshot in scrubs. A price, usually a range, sometimes a single all-in figure. And underneath all of it, the same two words doing most of the persuading: natural, and long-lasting.
What none of the roughly dozen Dubai pages we read for this piece show you is a form. Not the price form, a different one. Since 27 October 2021, a US surgeon has only been able to buy and use a breast implant if their practice uses a signed Patient Decision Checklist, a document the patient initials section by section and the operating physician signs personally, confirming she was walked through implant lifespan, rupture, a named rare cancer and more, before consent. It is the sharpest piece of paper in modern breast surgery, and across the Dubai clinic pages checked for this article, not one refers to it.
The stranger part is that the UAE was ahead of this, on paper, and does not appear to say so. In February 2019, two and a half years before the FDA's checklist existed, the UAE Ministry of Health and Prevention (MOHAP) issued guidance instructing practitioners to tell patients about implant risk and to screen for the same rare cancer the FDA later built its checklist around. Gulf News reported at the time that the instruction was issued as Administrative Circular No. 2501, signed by Dr Amin Hussein Al Amiri, then the ministry's Assistant Undersecretary for Public Health Policy and Licensing. Bellora was not able to locate the circular itself on mohap.gov.ae during research, so the number and signatory above are as reported by Gulf News, not independently confirmed against the primary document.
Two written instructions exist, from two different regulators, roughly two and a half years apart. Neither shows up on the sales pages selling the surgery they were written for.
The two documents nobody prints
Start with the timeline, because the order matters.
THE TIMELINE NOBODY PRINTS
March 2010
The PIP scandal, France
- What happened
- France's medical safety agency recalled Poly Implant Prothese implants after finding industrial-grade, not medical-grade, silicone inside
- Why it matters here
- It is the reason implant traceability and national registries exist as an idea at all
February 2019
A UAE instruction, ahead of the FDA
- What was reported
- MOHAP told practitioners to inform patients of implant risk and screen for a rare implant-linked cancer, per Gulf News reporting on an administrative circular
- Timing
- About two and a half years before the FDA's own boxed warning and checklist
July 2019
A global recall reaches Dubai
- What happened
- Allergan's Biocell textured implants and expanders were recalled worldwide. A named Dubai surgeon described his own monitoring protocol to Gulf News that July
- The gap
- That 2019 protocol does not match the FDA's later, official screening interval
October 2021
The FDA boxed warning and checklist
- What happened
- US sale of breast implants restricted to providers using a signed Patient Decision Checklist
- Checked in Dubai
- No clinic page read for this article references it
The circular itself sits in a genuine gap in the public record. We could not find its text published on a UAE government site, only Gulf News's contemporaneous account of it, so treat the circular's number and precise wording as reported, not verified first-hand. What is better documented is what happened five months later. On 24 July 2019, Allergan voluntarily recalled its Biocell textured implants and tissue expanders worldwide at the FDA's request. Gulf News quoted Dr Sanjay Parashar, then CEO of a Dubai aesthetic surgery centre, describing a monitoring schedule of six-monthly review for two years, then annually, with MRI scans at five and ten years. It is a real, named, on-record response from 2019. It is also the most recent one this research could find, and its scan schedule does not line up with the interval the FDA later formalised, which we set out below.
What the FDA's checklist actually makes you initial
The document itself, read in full from a working copy hosted by a US state medical board (a template marked "V1.0, 10/11/2021", not a fetch from fda.gov itself, worth stating plainly), asks a patient to initial next to ten separate risk sections and then sign, alongside the implanting physician, a final confirmation that both of them discussed it.
THE FDA PATIENT DECISION CHECKLIST
Not a lifetime device
Reoperation risk rises with time
- The line you initial
- The longer I have my implants, the more likely I am to need a reoperation
- A 10-year reference point
- 21.3 per cent explantation at 10 years in one augmentation-specific study, mostly by choice rather than complication
Rupture and silent rupture
MRI or ultrasound, on a schedule
- FDA's current interval
- First scan at 5 to 6 years after surgery, then every 2 to 3 years, for silicone implants
- One published series
- 14.0 per cent of 584 women screened had a rupture visible on scan
BIA-ALCL
Rare, and treatable when caught early
- FDA's own framing
- Individual risk is considered low. In most patients it is treated successfully by removing the implant and surrounding scar tissue
- Texture link
- Occurs more commonly with textured than smooth implants
- Symptom pattern
- Swelling, a lump, pain or asymmetry, developing after the surgical site has fully healed, often years later
Breast implant illness
A named but unresolved symptom cluster
- What it covers
- Joint pain, fatigue, brain fog and other systemic symptoms some patients attribute to their implants
- FDA's own caveat
- The causes of these symptoms are described as unclear
Who signs
Both of you
- The patient
- Initials next to every section, full signature at the end
- The physician
- Must sign personally. Not delegable to a resident or a coordinator
That checklist template still carries the older MRI interval (three years, then every two), which the FDA's own final guidance has since updated. Read FDA's actual current recommendation: for asymptomatic patients, "the first ultrasound or magnetic resonance imaging (MRI) should be performed at 5-6 years postoperatively, then every 2-3 years thereafter." We have used that newer interval throughout this article rather than the template's older figure, and flagged the discrepancy here because it is the kind of detail that quietly goes stale in a document nobody revisits.
Before any of that: implants themselves come in a handful of practical choices. Fill is silicone gel, which feels closer to natural tissue and can rupture silently, or saline, which deflates visibly and needs no MRI schedule because a rupture is self-evident. Shape is round, which can rotate with no visible change, or anatomical "teardrop", which looks wrong if it rotates and is therefore more often paired with a textured or adherent shell to stay in place. Plane is over the muscle (subglandular), under it (submuscular), or a dual-plane hybrid, a choice that turns out to matter more for complication risk than most menus let on, below.
Somewhere between that form and the surgery date is where the FDA now insists on a second one, initialled section by section.
Capsular contracture, rupture and the MRI you are not being quoted for
Capsular contracture, the body's scar tissue tightening around an implant until it feels hard or looks distorted, is graded on the Baker scale: I is normal, II is mild firmness with no visible change, III is moderate firmness with visible distortion, IV is severe, hard and often painful. Grades III and IV are the ones that typically need a second surgery.
The most current systematic review on this, Haas et al., Aesthetic Surgery Journal Open Forum, January 2025, found something that runs against instinct: smooth-surfaced implants carry a significantly higher contracture risk than textured ones (odds ratio 2.80), while placement under the muscle carries meaningfully lower risk than placement over it (odds ratio 0.35). Silicone versus saline showed no significant difference. The authors' own caveat, worth repeating whenever these ratios are quoted, is that the underlying evidence is still thin, citing a lack of large randomised trials.
2025 META-ANALYSIS
Smooth vs textured surface
Smooth carries higher risk
- Finding
- Odds ratio 2.80 for smooth vs textured (95 per cent CI 1.92 to 4.08)
- The trade-off
- Textured lowers contracture risk but is the surface linked to BIA-ALCL, below
Under vs over the muscle
Under the muscle carries lower risk
- Finding
- Odds ratio 0.35 for subpectoral vs prepectoral (95 per cent CI 0.25 to 0.50)
- The trade-off
- Submuscular placement is generally described as a harder first week of recovery
Silicone vs saline fill
No significant difference found
- Finding
- Odds ratio 0.39, but a wide confidence interval (0.02 to 6.69) from few directly comparable studies
10-year absolute rate, augmentation only
3.8 per cent Baker III or IV at 10 years
- Source
- One 10-year prospective study specific to primary augmentation, not reconstruction
- Elsewhere in the literature
- A separate pooled estimate, cited across sources but not independently confirmed to one named paper in our research, put the range at 7.6 to 25 per cent over 10 years. The spread itself is the honest fact
That 3.8 per cent figure comes from El-Haddad et al., Eplasty, 2018, a 10-year study specific to primary augmentation rather than reconstruction, and it is the single best-anchored "how likely is this to happen to me" number available. The same paper found implant rupture at 7.4 per cent at 10 years, and 21.3 per cent of patients had the implant removed with or without replacement by year ten, though the authors note only one and two of those explantations were attributed to contracture and rupture respectively, meaning most of that 21.3 per cent reflects a change of mind about size or shape, not a complication.
Rupture matters differently by fill type. Saline ruptures announce themselves; the breast visibly deflates within days, and no screening schedule is recommended because the problem is obvious. Silicone gel ruptures are frequently silent, because the cohesive gel tends to stay near the fibrous capsule rather than leaking freely, which is the entire reason the FDA's MRI schedule (first scan at 5–6 years, then every 2–3 years) exists. One published series screened 584 women with high-resolution ultrasound and found rupture on scan in 14.0 per cent of women and 8.0 per cent of individual implants; of those referred to surgery, three-quarters had the rupture surgically confirmed. No Dubai clinic page we read prices, or even names, that recurring screening scan. A patient is quoted a surgery fee with no visibility into what owning silicone implants responsibly is meant to cost her for the following decade.
The conversation that decides plane and surface is the one most likely to change the odds on the page above.
BIA-ALCL, in real numbers
Breast implant-associated anaplastic large cell lymphoma, BIA-ALCL, is a rare cancer of the immune system that forms in the fibrous capsule around an implant rather than in breast tissue itself. It is the reason the FDA's checklist exists, and it is also the topic most likely to be either ignored or overstated, so it deserves its own paragraph read in full rather than skimmed.
The FDA's own framing, worth quoting exactly because it holds two true things at once: "an individual's risk of developing BIA-ALCL is considered to be low; however, this cancer is serious and can lead to death, especially if not treated promptly. In most patients, it is treated successfully with surgery to remove the implant and surrounding scar tissue." Low individual risk, and high treatability when caught early, in the same sentence. That is the accurate frame, and this article keeps to it rather than either sensationalising the risk or waving it away.
On numbers: at the time of the 2019 Allergan recall, Gulf News reported FDA figures of 573 unique confirmed BIA-ALCL cases globally, 481 of them (84 per cent) linked to Allergan implants specifically, with 33 deaths confirmed at that point across all brands, 12 of them in patients with Allergan implants. A more recent figure circulating in patient-advocacy material cites over 1,300 cases and dozens of deaths tracked globally since 2011, with a median time from implant placement to diagnosis of around nine years. We have not been able to independently confirm that more recent figure against the FDA's own current published page in this research, so we are stating it here only as reported by that secondary source, not as a verified FDA count, and we are not printing an exact per-implant odds ratio for the same reason: the figures we found for that varied meaningfully between secondary sources and did not resolve to one FDA table we could confirm directly.
What is well established is the link to implant surface. BIA-ALCL occurs more commonly with textured implants than smooth ones, though the FDA itself notes rates are not precisely defined. The symptom pattern to know, because it is what actually prompts a diagnosis, is swelling, a lump, pain or asymmetry that develops after the surgical site has fully healed, often years afterwards, not in the days following surgery. No verified source found in this research states that textured implants are formally banned in the UAE; the accurate framing is that Allergan's specific recalled line left the global market in 2019, and Dubai's current major suppliers (Motiva, Mentor, Sebbin, Polytech among them) use different surface technologies, which is a narrower and more honest claim than "textured implants are banned here."
Why implants come out again, and how often
No single, universally agreed "revision rate" exists across the literature, and the honest range to give you is roughly 11 to 21 per cent at 10 years depending on the study and exactly what counts as a reoperation. What is consistent across the studies we reviewed is the ranking of why: cosmetic dissatisfaction or a wish to change size is, more often than not, the single largest driver, ahead of capsular contracture requiring correction, ahead of rupture requiring exchange, and well ahead of infection, malposition or BIA-ALCL. That ordering matters for how you read the next section, because it means a meaningful share of "redo" surgery in this field is a second decision, not a complication.
What Dubai actually charges
Published Dubai entry points for primary augmentation cluster between roughly AED 16,900 and AED 30,000, with several clinics publishing bands running to AED 40,000 to 44,000 at the premium or higher-complexity end.
INDICATIVE DUBAI PRICING
Not one of the Dubai price pages we read states whether its figure includes 5 per cent VAT. We are reporting that absence rather than assuming an answer either way. Inclusions vary just as widely: Clemenceau Medical Center (CMC) Dubai Hospital states plainly that its AED 30,000 covers consultation, pre-op mammography if needed, anaesthesia, implants, surgeon and theatre fees, one overnight stay, four follow-ups over 90 days and take-home medication. Most other Dubai pages we checked give a single number with no itemisation at all, which makes two clinics' "from AED 25,000" and "from AED 22,000" difficult to compare honestly against each other, let alone against CMC's fully-costed figure.
The number one hospital prints, and nobody else does
This is the sharpest, most checkable gap this research found, and it sits in plain sight on a hospital's own website. CMC Dubai Hospital runs three parallel package pages, built to the same template, for primary surgery and for two kinds of redo.
THE NUMBER MOST PAGES DON'T PRINT
Primary augmentation
AED 30,000
- Included
- Consultation, mammography if needed, anaesthesia, implants, surgeon and OT fees, one overnight stay, 4 follow-ups over 90 days, medication
- Surgeon named
- Dr Mahmoud Abu Dakka, stated as UK Board Certified and US Fellowship Trained
Implant replacement
AED 30,000
- What it is
- Like-for-like implant removal and exchange
- Included
- Same package structure as the primary surgery
- The point
- A straight swap costs the same as starting from zero
Full revision surgery
AED 35,000
- What it is
- The fuller corrective procedure, capsule work and repositioning, not just a swap
- The gap
- AED 5,000 above the primary and replacement figures, not itemised further on the page
Everywhere else checked
No published redo price
- Bizrahmed, Glamorous, Novomed
- Publish primary pricing only. Revision or explantation cost is not on the page
- What that means for a patient
- The number on the menu is not the number a revision will cost, and most Dubai pages do not say so
Read those three CMC figures together and the arithmetic is plain: a straight implant replacement costs the same as the original surgery, and a fuller revision costs about AED 5,000 more, because a redo repeats nearly the whole cost stack, surgeon, anaesthesia, facility and an overnight stay, a second time. That is not "half price," and it is not a small top-up fee, which is the assumption a patient quoted only for the first operation might reasonably carry into a second one. We are attributing this arithmetic to CMC specifically, built from its own three published prices, not generalising it to Dubai clinics as a class. Every other Dubai clinic checked for this article, Bizrahmed, Glamorous Clinic and Novomed among them, publishes a primary-surgery price and stops there.
Ask what a redo costs before you book the first one. One Dubai hospital already answers that question in writing. Most do not.
Dubai against Turkey and the UK
WHERE THE MONEY GOES
Dubai
AED 16,900 to AED 44,000
- All-in example
- AED 30,000 at CMC Dubai Hospital, one named surgeon
- Included
- Surgeon, anaesthesia, facility, implants. Garments and any screening MRI are not itemised anywhere we checked
- Why pay it
- A same-city surgeon for the following decade of screening and any revision
Turkey
About GBP 3,200 to 4,200 all-inclusive
- In AED
- About AED 15,900 to 20,900, an indicative conversion
- Included
- Surgeon, anaesthesia, implants (Mentor or Motiva named), one night hospital, hotel nights, transfers, tests, compression garments, medication, aftercare support
- The catch
- The FDA-recommended screening cycle and any revision sit a flight away
United Kingdom
GBP 3,500 to 8,000
- In AED
- About AED 17,400 to 39,800, an indicative conversion
- London specifically
- GBP 6,500 to 9,500, about AED 32,300 to 47,300
- Note
- An average cited around GBP 4,500 across UK sources
None of this is apples to apples until you say plainly what each figure buys. Dubai's published numbers are, in nearly every case checked, a surgeon and facility fee only. The Turkish packages we found genuinely include far more, hotel nights, transfers and aftercare support among them, so a lower headline figure is not automatically a cheaper real cost. The case for staying local is structural rather than purely financial: a named, licensed surgeon in the same city for a decade of screening scans and any revision, rather than a return flight for a routine MRI or a complication, plus recourse under UAE medical liability law and the DHA's own complaints route, neither of which follows a patient home from abroad.
The facility rule, and the registry question nobody can answer yet
Dubai regulates where this surgery can happen, in a way none of the clinic pages we read mention on their own site. The DHA's Standards for Standalone Day Surgery Centres, Version 3.1 (2021), lists "breast implants and augmentation" at a minimum facility Class C, the day-surgery tier rather than hospital-only, requiring a full-time medical director, a specialist or consultant surgeon and an anaesthetist present until the patient is discharged, and defined resuscitation equipment on site. Version 4, the document currently in effect, moved that procedure-by-procedure classification table out of its own text and into a separate published list, which we were unable to retrieve during this research; we can therefore report what the 2021 standard required with confidence, but cannot state that Class C remains the current minimum for this procedure as a flat, present-day fact. Treat it as very likely still true, not confirmed.
No UAE national breast implant registry appears in the MOHAP or DHA documents we checked. We are reporting that as an absence found in the documents this research reviewed, not as proof that no such requirement exists anywhere in UAE law. It matters because of what happened in France in 2010: a manufacturer called Poly Implant Prothese was found to have used unapproved, industrial-grade silicone in place of medical-grade silicone in its implants, prompting a recall and, eventually, criminal liquidation. Roughly 400,000 women worldwide, an estimated 50,000 of them in the UK, had received PIP implants. A market with no implant registry has no independent, fast way to identify every patient who received a specific recalled device; it depends on the clinic's own records and on the patient having kept her own implant card.
Who is allowed to operate, and what to ask before you sign
Dubai's Standards for Standalone Day Surgery Centres set a general two-part informed-consent structure for any Class C procedure: an information sheet covering the procedure, risks, complications, alternatives and financial implications, and a certificate of consent signed by the patient, a witness and the treating physician. That is DHA's baseline for day surgery generally. It is not the itemised, implant-specific checklist the FDA now requires in the United States, and no Dubai clinic page we checked states that it uses anything equivalent.
None of this is a claim that any named Dubai clinic is falling short of what its own consultation room actually does; this research checked public marketing pages, not clinical practice or a specific patient's paperwork, and it would be unfair to infer the second from the first. It is a narrower, more useful point: the tool this article can hand you is a set of questions, not an accusation. Ask which document, if any, you will be asked to initial section by section. Ask what your own MRI or ultrasound schedule will look like for the next decade, and whether that cost sits inside your quoted price or outside it. Ask, plainly, what it would cost to redo or remove the implants if you change your mind, since one Dubai hospital already answers that question in writing and there is no reason every other one could not.
For a comparable surgical-cosmetic decision with its own facility and cost questions, see our piece on liposuction and tummy tuck in Dubai. If proximity to a UAE clinic for aftercare and screening is part of your own calculation against travelling abroad, our wider look at medical tourism into Dubai covers that trade-off in more depth. Two Dubai-listed clinics in Bellora's directory publish a wide breast-specific service range worth a look if you are at the comparison stage: Dr Rory McGoldrick, who lists breast augmentation, lift, reduction and reconstruction, and Dr Abizer Kapadia, who lists augmentation, reduction and lift alongside body-contouring work. The wider set of surgeons and clinics offering this procedure sits in our Plastic & Cosmetic Surgery directory, part of the full Bellora directory.
Common questions
How much does breast augmentation cost in Dubai?
Published entry points run from about AED 16,900 to AED 30,000 depending on clinic and implant tier, with several premium or high-complexity bands reaching AED 40,000 to 44,000. One hospital, CMC Dubai, publishes a single itemised all-in figure of AED 30,000. No page we checked states whether its figure includes VAT.
Are breast implants safe?
They carry real, well-documented risks: capsular contracture, rupture, reoperation over time, and a rare cancer called BIA-ALCL. The FDA's own position, worth repeating exactly, is that an individual's BIA-ALCL risk is considered low and that most cases are treated successfully once caught. Safety here is a matter of informed, ongoing management, screening scans on schedule, symptom awareness, a named surgeon, rather than a single yes-or-no answer.
What is BIA-ALCL and how likely am I to get it?
A rare cancer of the immune system that forms in the scar capsule around an implant, more commonly linked to textured than smooth implant surfaces. We are not printing an exact per-implant odds figure here because the numbers we found varied between secondary sources and did not resolve to one confirmed FDA table. What is consistent across every primary source we checked: individual risk is considered low, and most cases, caught early through its typical symptom pattern of delayed swelling, a lump or asymmetry, are treated successfully.
How long do breast implants last before they need replacing?
The FDA's own position is that implants are "not considered lifetime devices," and that the longer someone has them, the greater the chance of eventually needing further surgery. In one 10-year study specific to primary augmentation, 21.3 per cent of patients had their implants removed, with or without replacement, by year ten, though cosmetic choice rather than complication was the most common reason.
Do I need an MRI after getting breast implants, and how often?
For silicone implants, the FDA's current recommendation is a first ultrasound or MRI at five to six years after surgery, then every two to three years afterwards for anyone without symptoms. Saline implants need no such schedule, because a rupture is visibly obvious. No Dubai clinic page we checked prices or names this recurring screening cost.
What is capsular contracture and how common is it?
Scar tissue tightening around the implant, graded Baker I to IV, with III and IV usually needing correction. One 10-year study specific to augmentation found a 3.8 per cent rate of Baker III or IV contracture; other pooled reviews report a wider range, up to roughly 25 per cent over ten years across mixed study types. The spread between studies is itself worth knowing, not just one number from it.
Silicone or saline, which is safer?
The most current meta-analysis found no statistically significant difference in contracture risk between the two. The practical difference is elsewhere: silicone feels closer to natural tissue and can rupture silently, which is why it carries an MRI schedule; saline ruptures are self-evident and need no such schedule.
Round or teardrop (anatomical) implants, what is the difference?
Round implants can rotate with no visible change. Anatomical, teardrop-shaped implants look wrong if they rotate, which is part of why they are more often paired with a textured or adherent shell, linking the shape choice to the surface-texture conversation above.
Implant under or over the muscle, which is better?
Under the muscle (subpectoral) carries meaningfully lower capsular contracture risk in the current meta-analysis (odds ratio 0.35 versus over the muscle), but is generally described as a harder first week of recovery and can distort visibly with pectoral muscle flexion, which prepectoral placement does not.
How much does it cost to replace or revise breast implants in Dubai?
At CMC Dubai Hospital, a like-for-like implant replacement is priced the same as the original surgery, AED 30,000, and a fuller revision is priced at AED 35,000. No other Dubai clinic checked for this article publishes a comparable revision or replacement figure at all.
What is "breast implant illness" and is it real?
A named cluster of systemic symptoms, including joint pain, fatigue and brain fog, that some patients attribute to their implants. The FDA's own position is that the causes are unclear. It is included on the FDA's patient checklist as something a patient should be told about, not as a settled diagnosis.
Do breast implants affect breastfeeding or mammograms?
Implants can interfere with mammography and potentially delay diagnosis, which is why patients are asked to tell the mammography technologist about their implants beforehand. Breastfeeding interference, along with changes to nipple or breast sensation, are both listed among the standard risks a patient should be told before surgery.
Is breast augmentation cheaper in Turkey than in Dubai, and what is the catch?
Turkey's published all-inclusive packages, roughly GBP 3,200 to 4,200 (about AED 15,900 to 20,900), often undercut Dubai's headline figures, but they bundle in hotel nights, transfers and aftercare that most Dubai prices do not include as a comparable line item. The trade-off is proximity: the FDA-recommended screening schedule and any future revision sit a flight away rather than a short drive.
What should be in an informed consent form before breast implant surgery?
Dubai's own day-surgery standard requires an information sheet covering the procedure, risks, complications and financial implications, plus a signed certificate of consent from the patient, a witness and the physician. That is a general day-surgery baseline, not the FDA's itemised, implant-specific checklist. No Dubai clinic page we checked states that it uses anything equivalent to the FDA document.
Sources and methodology
Prices in this article are indicative 2026 market estimates read from published Dubai and hospital price pages on a stated date, attributed to the page that published them, never blended into a single market average. Clinical figures are given with their study design and sample size, because in a topic like this the design is part of the finding: a systematic review, a single-centre prospective study and a manufacturer-funded dataset are three different kinds of evidence. Where a figure in the underlying research could not be independently confirmed against a primary source (the most recent FDA BIA-ALCL case count, the exact per-implant BIA-ALCL odds, DHA's current facility-classification list, and one pooled capsular-contracture range among them), we have said so in the text rather than presenting it as settled fact. We review this article periodically and update it as menus, studies and standards change.
- Breast Implants – Certain Labeling Recommendations to Improve Patient Communication, US Food and Drug Administration, guidance issued 29 September 2020
- Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), US FDA
- FDA issues new labeling and informed-consent requirements for breast implants, American Society of Plastic Surgeons, 27 October 2021
- Allergan Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders, US FDA, 24 July 2019
- Warning: UAE issues caution against silicone breast implants, Gulf News, 20 February 2019
- UAE surgeons confirm breast implant recall notice, Gulf News, 29 July 2019
- Standards for Standalone Day Surgery Centres, Version 3.1, Dubai Health Authority, 2021
- Haas E et al, Capsular Contracture After Breast Augmentation: A Systematic Review and Meta-Analysis, Aesthetic Surgery Journal Open Forum, 15 January 2025
- El-Haddad R et al, A 10-Year Prospective Study of Implant-Based Breast Augmentation and Reconstruction, Eplasty, 2018
- Hillard C et al, Silent Rupture of Silicone Gel Breast Implants: High-Resolution Ultrasound Scans and Surveys of 584 Women, 2022
- Breast Augmentation Package, Breast Implant Replacement Package and Breast Revision Surgery Package, Clemenceau Medical Center Dubai Hospital
This is informational and is not individual medical advice. Confirm anything specific to your own health, implant history or surgical plan with a licensed clinic and with the named surgeon who would perform the procedure.